BIOMAT Database Logo BIOMAT Database Logo

Genetic variation in the alpha 7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer's disease. 2008

Robyn Carson, and David Craig, and Dominic Hart, and Stephen Todd, and Bernadette McGuinness, and Janet A Johnston, and Francis A O'Neill, and Craig W Ritchie, and A Peter Passmore
Division of Psychiatry and Neuroscience, School of Medicine and Dentistry, Queen's University Belfast, Whitla Medical Building, 97 Lisburn Road, Belfast, BT9 7BL, Northern Ireland, UK. robyn.carson@qub.ac.uk

Psychotic symptoms are common in Alzheimer's disease (AD) and have a negative impact on quality of life. It is suggested that psychotic symptoms may be attributed to genetic risk factors which are revealed during neurodegeneration. CHRNA7, the gene for the alpha 7 nicotinic acetylcholine receptor, has been associated with schizophrenia in linkage and association studies. Hence we investigated single SNPs and haplotypes in CHRNA7 in relation to AD with psychosis in a large, well-characterised and previously described cohort within the Northern Ireland population. A significant association between delusions and the T allele of rs6494223 (P = 0.014, OR = 1.63, CI = 1.22-2.17) was found. This suggests that the alpha 7 receptor may be a suitable target for the treatment of AD with psychosis.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009435 Synaptic Transmission The communication from a NEURON to a target (neuron, muscle, or secretory cell) across a SYNAPSE. In chemical synaptic transmission, the presynaptic neuron releases a NEUROTRANSMITTER that diffuses across the synaptic cleft and binds to specific synaptic receptors, activating them. The activated receptors modulate specific ion channels and/or second-messenger systems in the postsynaptic cell. In electrical synaptic transmission, electrical signals are communicated as an ionic current flow across ELECTRICAL SYNAPSES. Neural Transmission,Neurotransmission,Transmission, Neural,Transmission, Synaptic
D011978 Receptors, Nicotinic One of the two major classes of cholinergic receptors. Nicotinic receptors were originally distinguished by their preference for NICOTINE over MUSCARINE. They are generally divided into muscle-type and neuronal-type (previously ganglionic) based on pharmacology, and subunit composition of the receptors. Nicotinic Acetylcholine Receptors,Nicotinic Receptors,Nicotinic Acetylcholine Receptor,Nicotinic Receptor,Acetylcholine Receptor, Nicotinic,Acetylcholine Receptors, Nicotinic,Receptor, Nicotinic,Receptor, Nicotinic Acetylcholine,Receptors, Nicotinic Acetylcholine
D001923 Brain Chemistry Changes in the amounts of various chemicals (neurotransmitters, receptors, enzymes, and other metabolites) specific to the area of the central nervous system contained within the head. These are monitored over time, during sensory stimulation, or under different disease states. Chemistry, Brain,Brain Chemistries,Chemistries, Brain
D004252 DNA Mutational Analysis Biochemical identification of mutational changes in a nucleotide sequence. Mutational Analysis, DNA,Analysis, DNA Mutational,Analyses, DNA Mutational,DNA Mutational Analyses,Mutational Analyses, DNA
D005260 Female Females
D005787 Gene Frequency The proportion of one particular in the total of all ALLELES for one genetic locus in a breeding POPULATION. Allele Frequency,Genetic Equilibrium,Equilibrium, Genetic,Allele Frequencies,Frequencies, Allele,Frequencies, Gene,Frequency, Allele,Frequency, Gene,Gene Frequencies
D005819 Genetic Markers A phenotypically recognizable genetic trait which can be used to identify a genetic locus, a linkage group, or a recombination event. Chromosome Markers,DNA Markers,Markers, DNA,Markers, Genetic,Genetic Marker,Marker, Genetic,Chromosome Marker,DNA Marker,Marker, Chromosome,Marker, DNA,Markers, Chromosome
D005820 Genetic Testing Detection of a MUTATION; GENOTYPE; KARYOTYPE; or specific ALLELES associated with genetic traits, heritable diseases, or predisposition to a disease, or that may lead to the disease in descendants. It includes prenatal genetic testing. Genetic Predisposition Testing,Genetic Screening,Predictive Genetic Testing,Predictive Testing, Genetic,Testing, Genetic Predisposition,Genetic Predictive Testing,Genetic Screenings,Genetic Testing, Predictive,Predisposition Testing, Genetic,Screening, Genetic,Screenings, Genetic,Testing, Genetic,Testing, Genetic Predictive,Testing, Predictive Genetic

Related Publications

Robyn Carson, and David Craig, and Dominic Hart, and Stephen Todd, and Bernadette McGuinness, and Janet A Johnston, and Francis A O'Neill, and Craig W Ritchie, and A Peter Passmore
Role of Alpha-7-Nicotinic Acetylcholine Receptor in Alzheimer's Disease.
January 2024, CNS & neurological disorders drug targets,
Robyn Carson, and David Craig, and Dominic Hart, and Stephen Todd, and Bernadette McGuinness, and Janet A Johnston, and Francis A O'Neill, and Craig W Ritchie, and A Peter Passmore
Alpha 7 nicotinic acetylcholine receptor and its effects on Alzheimer's disease.
February 2019, Neuropeptides,
Robyn Carson, and David Craig, and Dominic Hart, and Stephen Todd, and Bernadette McGuinness, and Janet A Johnston, and Francis A O'Neill, and Craig W Ritchie, and A Peter Passmore
Increased alpha 7 nicotinic acetylcholine receptor protein levels in Alzheimer's disease patients.
January 2005, Dementia and geriatric cognitive disorders,
Robyn Carson, and David Craig, and Dominic Hart, and Stephen Todd, and Bernadette McGuinness, and Janet A Johnston, and Francis A O'Neill, and Craig W Ritchie, and A Peter Passmore
Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons.
January 2006, Current pharmaceutical design,
Robyn Carson, and David Craig, and Dominic Hart, and Stephen Todd, and Bernadette McGuinness, and Janet A Johnston, and Francis A O'Neill, and Craig W Ritchie, and A Peter Passmore
[Nicotinic acetylcholine receptor in Alzheimer's disease].
April 2013, Nihon rinsho. Japanese journal of clinical medicine,
Robyn Carson, and David Craig, and Dominic Hart, and Stephen Todd, and Bernadette McGuinness, and Janet A Johnston, and Francis A O'Neill, and Craig W Ritchie, and A Peter Passmore
Dissociating beta-amyloid from alpha 7 nicotinic acetylcholine receptor by a novel therapeutic agent, S 24795, normalizes alpha 7 nicotinic acetylcholine and NMDA receptor function in Alzheimer's disease brain.
September 2009, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Robyn Carson, and David Craig, and Dominic Hart, and Stephen Todd, and Bernadette McGuinness, and Janet A Johnston, and Francis A O'Neill, and Craig W Ritchie, and A Peter Passmore
Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease.
January 2002, Neuroscience,
Robyn Carson, and David Craig, and Dominic Hart, and Stephen Todd, and Bernadette McGuinness, and Janet A Johnston, and Francis A O'Neill, and Craig W Ritchie, and A Peter Passmore
Alpha 7 nicotinic acetylcholine receptor modulates lymphocyte activation.
September 2009, Life sciences,
Robyn Carson, and David Craig, and Dominic Hart, and Stephen Todd, and Bernadette McGuinness, and Janet A Johnston, and Francis A O'Neill, and Craig W Ritchie, and A Peter Passmore
Alzheimer's disease is associated with a selective increase in alpha7 nicotinic acetylcholine receptor immunoreactivity in astrocytes.
January 2003, Glia,
Robyn Carson, and David Craig, and Dominic Hart, and Stephen Todd, and Bernadette McGuinness, and Janet A Johnston, and Francis A O'Neill, and Craig W Ritchie, and A Peter Passmore
Variation in nicotinic acetylcholine receptor genes is associated with multiple substance dependence phenotypes.
August 2010, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Copied contents to your clipboard!